Rights statement: The final, definitive version of this article has been published in the Journal, Statistical Methods in Medical Research, 25 (3), 2016, © SAGE Publications Ltd, 2016 by SAGE Publications Ltd at the Statistical Methods in Medical Research page: http://smm.sagepub.com/ on SAGE Journals Online: http://online.sagepub.com/
Accepted author manuscript, 431 KB, PDF document
Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License
Final published version
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - A review of statistical designs for improving the efficiency of phase II studies in oncology
AU - Wason, James
AU - Jaki, Thomas
N1 - The final, definitive version of this article has been published in the Journal, Statistical Methods in Medical Research, 25 (3), 2016, © SAGE Publications Ltd, 2016 by SAGE Publications Ltd at the Statistical Methods in Medical Research page: http://smm.sagepub.com/ on SAGE Journals Online: http://online.sagepub.com/
PY - 2016/6
Y1 - 2016/6
N2 - Phase II oncology trials are carried out to assess whether an experimental anti-cancer treatment shows sufficient signs of effectiveness to justify being tested in a phase III trial. Traditionally such trials are conducted as single-arm studies using a binary response rate as the primary endpoint. In this article, we review and contrast alternative approaches for such studies. Each approach uses only data that are necessary for the traditional analysis. We consider two broad classes of methods: ones that aim to improve the efficiency using novel design ideas, such as multi-stage and multi-arm multi-stage designs; and ones that aim to improve the analysis, by making better use of the richness of the data that is ignored in the traditional analysis. The former class of methods provides considerable gains in efficiency but also increases the administrative and logistical issues in running the trial. The second class consists of viable alternatives to the standard analysis that come with little additional requirements and provide considerable gains in efficiency.
AB - Phase II oncology trials are carried out to assess whether an experimental anti-cancer treatment shows sufficient signs of effectiveness to justify being tested in a phase III trial. Traditionally such trials are conducted as single-arm studies using a binary response rate as the primary endpoint. In this article, we review and contrast alternative approaches for such studies. Each approach uses only data that are necessary for the traditional analysis. We consider two broad classes of methods: ones that aim to improve the efficiency using novel design ideas, such as multi-stage and multi-arm multi-stage designs; and ones that aim to improve the analysis, by making better use of the richness of the data that is ignored in the traditional analysis. The former class of methods provides considerable gains in efficiency but also increases the administrative and logistical issues in running the trial. The second class consists of viable alternatives to the standard analysis that come with little additional requirements and provide considerable gains in efficiency.
KW - augmented methods
KW - continuous
KW - multi-stage
KW - phase II
KW - RECIST
KW - oncology
U2 - 10.1177/0962280215588247
DO - 10.1177/0962280215588247
M3 - Journal article
VL - 25
SP - 1010
EP - 1021
JO - Statistical Methods in Medical Research
JF - Statistical Methods in Medical Research
SN - 0962-2802
IS - 3
ER -